NuCana PLC (NCNA) - Total Assets
Based on the latest financial reports, NuCana PLC (NCNA) holds total assets worth $29.78 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of NuCana PLC to assess how comfortably operating cash covers total debt obligations.
NuCana PLC - Total Assets Trend (2014–2025)
This chart illustrates how NuCana PLC's total assets have evolved over time, based on quarterly financial data. See NuCana PLC book value and equity for net asset value and shareholders' equity analysis.
NuCana PLC - Asset Composition Analysis
Current Asset Composition (December 2025)
NuCana PLC's total assets of $29.78 Million consist of 90.0% current assets and 10.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 81.3% |
| Accounts Receivable | $1.76 Million | 5.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.19 Million | 7.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how NuCana PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of NuCana PLC.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NuCana PLC's current assets represent 90.0% of total assets in 2025, a decrease from 98.4% in 2014.
- Cash Position: Cash and equivalents constituted 81.3% of total assets in 2025, down from 94.6% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 1.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 7.4% of total assets.
NuCana PLC Competitors by Total Assets
Key competitors of NuCana PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
NuCana PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.60 | 1.25 | 10.47 |
| Quick Ratio | 5.60 | 1.25 | 10.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $22.03 Million | $1.83 Million | $85.90 Million |
NuCana PLC - Advanced Valuation Insights
This section examines the relationship between NuCana PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.27 |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | 101.6% |
| Total Assets | $29.78 Million |
| Market Capitalization | $5.49 Million USD |
Valuation Analysis
Below Book Valuation: The market values NuCana PLC's assets below their book value (0.18x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: NuCana PLC's assets grew by 101.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for NuCana PLC (2014–2025)
The table below shows the annual total assets of NuCana PLC from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $29.78 Million | +101.58% |
| 2024-12-31 | $14.77 Million | -46.88% |
| 2023-12-31 | $27.81 Million | -52.26% |
| 2022-12-31 | $58.25 Million | -24.81% |
| 2021-12-31 | $77.47 Million | -28.13% |
| 2020-12-31 | $107.79 Million | +53.40% |
| 2019-12-31 | $70.27 Million | -19.40% |
| 2018-12-31 | $87.19 Million | -9.52% |
| 2017-12-31 | $96.36 Million | +254.06% |
| 2016-12-31 | $27.21 Million | -14.11% |
| 2015-12-31 | $31.68 Million | +88715.70% |
| 2014-12-31 | $35.67K | -- |
About NuCana PLC
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metab… Read more